HOLLISTON, Mass., Feb. 23, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2016 after market trading hours on Thursday, March 9, 2017. A conference call to discuss the company's fourth quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 44422279.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 16, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Washington Post Publisher Will Lewis Steps Down After Layoffs
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



